Last updated: 2026-09-30 22:43:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
TransCode Therapeutics, Inc. (RNAZ) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.65, with a market capitalization of $28.95M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.58 to $20.99. This page covers its latest market performance, valuation, price trends and company information.
$28.95M | |
$1.66 | |
$5,174,400.00 | |
$1.58 | |
$1.63 | |
6.55K | |
53.58K | |
-- | |
$20.99 | |
$1.58 | |
-- | |
-- |
TransCode Therapeutics, Inc. (RNAZ) is trading at $1.64 in after-hours trading as of 2026-09-30 21:39:00, up 0.80% ($0.01) from the regular-session close of $1.63.
After-hours trading shows how investors are pricing RNAZ after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, TransCode Therapeutics, Inc. (RNAZ) moved from $1.76 to $1.65, representing a decline of 6.25% ($0.11).
The stock traded between $1.60 and $2.39 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 92.36 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.4%
RNAZ is currently trading at $1.65, placing it 0.4% of the way from its 52-week low of $1.58 to its 52-week high of $20.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of TransCode Therapeutics, Inc. (RNAZ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.